[ad_1]
The British drug manufacturer AstraZeneca (LSE: AZN) has obtained a favorable reimbursement recommendation for its PARP inhibitor Lynparza (olaparib), through the Cancer Fund (CDF).
The therapy will be funded as an option for the maintenance treatment of some people with epithelial carcinoma of the ovary, a fallopian tube or a primary cancer of the BRCA mutation peritome.
Mohit Manrao, Director of Oncology Division at AstraZeneca UK, said: "We have worked together with NICE and NHS England and are extremely proud to have reached today's decision."
AstraZeneca has developed therapy, the world's leading PARP inhibitor, in conjunction with Merck & Co (NYSE: MRK), as part of a 2017 agreement up to $ 8.5 billion.
The companies have agreed to share the costs of developing and marketing Lynparza as monotherapy and PD-L1 / PD-1-free combination therapies. The gross profits generated by sales generated by monotherapies or combination therapies will be shared equally.
Louise Houson, Managing Director of Merck UK, said: "Olaparib is the only drug in its clbad to have demonstrated significant and clinically significant improvement in the risk of progression in women who have recently been diagnosed with advanced ovarian cancer with mutation of the BRCA gene, chemotherapy-based. "
[ad_2]
Source link
